Kärkkäinen J, Räisänen M
Department of Medical Chemistry, University of Helsinki, Finland.
Biol Psychiatry. 1992 Dec 1;32(11):1042-8. doi: 10.1016/0006-3223(92)90066-9.
Nialamide, an MAO inhibitor, was given per os (PO) to a normal man who volunteered in two separate trials (total intake 300 mg and 1000 mg, respectively), and his bufotenin excretion was followed by consecutive urine samples. In both experiments the excretion rose well above the values measured from the same test subject when not taking nialamide (median 0.089 nmol/mmol creatinine, range 0.002-1.78). At its highest, the excretion was 16.5 nmol/mmol creatinine, and the maximum urinary output was 495 nmoles (56 micrograms) in 24 hr. The levels of bufotenin in plasma required for the excretion of the latter amounts are not far from those that produce psychic symptoms in man.
尼亚拉胺,一种单胺氧化酶抑制剂,在两项独立试验中口服给予一名自愿参与的正常男性(分别摄入总量为300毫克和1000毫克),并通过连续采集尿液样本跟踪其蟾蜍色胺排泄情况。在两项实验中,排泄量均远高于该受试对象在未服用尼亚拉胺时测得的值(中位数为0.089纳摩尔/毫摩尔肌酐,范围为0.002 - 1.78)。排泄量最高时为16.5纳摩尔/毫摩尔肌酐,24小时内最大尿量为495纳摩尔(56微克)。产生上述排泄量所需的血浆中蟾蜍色胺水平与在人体中产生精神症状的水平相差不远。